Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1995 2
1998 1
1999 1
2000 3
2001 3
2002 3
2003 3
2004 1
2005 2
2006 1
2008 2
2010 2
2011 11
2012 13
2013 12
2014 17
2015 21
2016 12
2017 21
2018 20
2019 10
2020 14
2021 15
2022 16
2023 15
2024 9
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. Rugo HS, et al. Among authors: motwani m. Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23. Lancet. 2023. PMID: 37633306 Free article. Clinical Trial.
Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.
Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, Botezatu S, Aslam S, Lewis S, Graham C, White AC, MacGillivray T, Tuck CE, Rayson P, Cranley D, Irvine S, Armstrong R, Milne L, Chin CWL, Hillis GS, Fairbairn T, Greenwood JP, Steeds R, Leslie SJ, Lang CC, Bucciarelli-Ducci C, Joshi NV, Kunadian V, Vassiliou VS, Dungu JN, Hothi SS, Boon N, Prasad SK, Keenan NG, Dawson D, Treibel TA, Motwani M, Miller CA, Mills NL, Rajani R, Ripley DP, McCann GP, Prendergast B, Singh A, Newby DE, Dweck MR; EVOLVED investigators. Loganath K, et al. Among authors: motwani m. JAMA. 2025 Jan 21;333(3):213-221. doi: 10.1001/jama.2024.22730. JAMA. 2025. PMID: 39466640 Free PMC article. Clinical Trial.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Camidge DR, et al. Among authors: motwani m. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288547 Free PMC article. Clinical Trial.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. Strickler JH, et al. Among authors: motwani m. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. J Clin Oncol. 2018. PMID: 30285518 Free article. Clinical Trial.
Implementation of a national AI technology program on cardiovascular outcomes and the health system.
Fairbairn TA, Mullen L, Nicol E, Lip GYH, Schmitt M, Shaw M, Tidbury L, Kemp I, Crooks J, Burnside G, Sharma S, Chauhan A, Liew C, Waidyanatha S, Iyenger S, Beale A, Sunderji I, Greenwood JP, Motwani M, Reid A, Beattie A, Carter J, Haworth P, Bellenger N, Hudson B, Rodrigues J, Watson O, Venugopal V, Bull R, O'Kane P, Deshpande A, McCann GP, Duckett S, Mansoubi H, Parish V, Sehmi J, Rogers C, Mullen S, Weir-McCalL J. Fairbairn TA, et al. Among authors: motwani m. Nat Med. 2025 Jun;31(6):1903-1910. doi: 10.1038/s41591-025-03620-y. Epub 2025 Apr 4. Nat Med. 2025. PMID: 40186078 Free PMC article.
Sex Differences in the Genetic Causes of Dilated Cardiomyopathy.
Mangino M, McGurk KA, Theotokis P, Buchan RJ, Stockwell CR, Thami PK, Jennings E, Wan E, Enright C, Adlan A, Akbari T, Baksi J, Barton PJR, Berry C, Carr-White G, Chiribiri A, Cooper R, Dattani A, Flett AS, Gardner RS, Greenwood JP, Halliday BP, Hammersley DJ, Hutchings DC, Mahmod M, Marrow B, McCann GP, Motwani M, Neubauer S, O' Regan DP, Page SP, Pantazis A, Peebles C, Raman B, Swoboda PP, Varnava A, Venetucci L, Watkins H, Wright D, Prasad SK, Cook SA, Ware JS, Tayal UP; GO-DCM Investigators. Mangino M, et al. Among authors: motwani m. J Am Coll Cardiol. 2025 Aug 5;86(5):400-403. doi: 10.1016/j.jacc.2025.04.068. J Am Coll Cardiol. 2025. PMID: 40738566 Free PMC article. No abstract available.
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Camidge DR, et al. Among authors: motwani m. Clin Cancer Res. 2021 Nov 1;27(21):5781-5792. doi: 10.1158/1078-0432.CCR-21-0765. Epub 2021 Aug 23. Clin Cancer Res. 2021. PMID: 34426443 Free PMC article. Clinical Trial.
cGAS Micro-Manages Genotoxic Stress.
Motwani M, Fitzgerald KA. Motwani M, et al. Immunity. 2017 Oct 17;47(4):616-617. doi: 10.1016/j.immuni.2017.09.020. Immunity. 2017. PMID: 29045895 Free article.
223 results